The therapeutic potential of flavonoids

Bibliography

• WANG HK, XIA Y, YANG ZY, NATSCHKE SL, LEE KH: Recent advances in the discovery and development of flavonoids and their analogues as antitumor and an ti-1-11V agen ts. Adv. Exp. Med. Biol. (1998) 439:191–225.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review that covers antitumour andanti-HIV effects of flavonoids.
   Google Scholar
• HARMON AD, WEISS U, SILVERTON JV: The structure of rohitukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Meliaceae). THL (1979):721–724.
   Google Scholar
• BIBLE KC, KAUFMANN SH: Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. (1996) 56:4856–4861.
   PubMed Web of Science ®Google Scholar
• •The first report regarding the cytotoxicity of flavopiridol.
   Google Scholar
• PATEL V, SENDEROWICZ AM, PINTO D, JR. et al.:Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Clin. Invest. (1998) 102:1674–1681.
   Google Scholar
• WRIGHT J, BLATNER GL, CHESON BD: Clinical trialsreferral resource. Clinical trials of flavopiridol. Oncology (1998) 12:1018–1014.
   Google Scholar
• SCHRUMP DS, MATTHEWS W, CHEN GA, MIXON A, ALTORKI NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin. Cancer Res. (1998) 4:2885–2890.
   PubMed Web of Science ®Google Scholar
• BYRD JC, SHINN C, WASELENKO JK et al.: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bc1-2 modulation or dependence on functional p53. Blood (1998) 92:3804–3816.
   PubMed Web of Science ®Google Scholar
• PARKER BW, KAUR G, NIEVES-NEIRA W et al.: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 91:458–465.
   PubMed Web of Science ®Google Scholar
• BRUSSELBACH S, NETTELBECK DM, SEDLACEK HH,MULLER R: Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int. J. Cancer (1998) 77:146–152.
   PubMed Web of Science ®Google Scholar
• SHAPIRO GI, KOESTNER DA, MATRANGA CB, ROLLINS BJ:Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. (1999) 5:2925–2938.
   PubMed Web of Science ®Google Scholar
• CHIEN M, ASTUMIAN M, LIEBOWITZ D, RINKER-SCHAEFFER C, STADLER WM: In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother. Pharmacol. (1999) 44:81–87.
   PubMed Web of Science ®Google Scholar
• LI Y, BHUIYAN M, ALHASAN S, SENDEROWICZ AM, SARKAR FH: Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin. Cancer Res. (2000) 6:223–229.
   PubMed Web of Science ®Google Scholar
• DREES M, DENGLER WA, ROTH T et al.: Flavopiridol(U6-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. (1997) 3:273–279.
   PubMed Web of Science ®Google Scholar
• ARGUELLO F, ALEXANDER M, STERRY JA et al.:Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood (1998) 91:2482–2490.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GK, FARSI K, MASLAK P, KELSEN DP, SPRIGGSD: Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res. (1997) 3:1467–1472.
   PubMed Web of Science ®Google Scholar
• BIBLE KC, KAUFMANN SH: Cy to to x ic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. (1997) 57:3375–3380.
   PubMed Web of Science ®Google Scholar
• •A study regarding the administrational sequence of flavopiridol with various antineoplastic agents.
   Google Scholar
• MOTVVANI M, DELOHERY TM, SCHWARTZ GK: Sequen-tial dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. an. Cancer Res. (1999) 5:1876–1883.
   Web of Science ®Google Scholar
• SAUSVILLE EA, ZAHAREVITZ D, GUSSIO R et al: Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. (1999) 82:285–292.
   PubMed Web of Science ®Google Scholar
• DE AZEVEDO WF, JR., MUELLER-DIECKMANN HJ, SCHULZE-GAHMEN U, WORLAND PJ, SAUSVILLE E, KIM SH: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA (1996) 93:2735–2740.
   PubMed Web of Science ®Google Scholar
• CARLSON B, LAHUSEN T, SINGH S et al.:Down-regulation of cyclin Di by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. (1999) 59:4634–4641.
   PubMed Web of Science ®Google Scholar
• KONIG A, SCHWARTZ GK, MOHAMMAD RM, AL KATIB A,GABRILOVE JL: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bc1-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood (1997) 90:4307–4312.
   PubMed Web of Science ®Google Scholar
• HOOIJBERG JH, BROXTERMAN HJ, SCHEFFER GL et al:Potent interaction of flavopiridol with MRP1. Br. J Cancer (1999) 81:269–276.
   PubMed Web of Science ®Google Scholar
• MELILLO G, SAUSVILLE EA, CLOUD K, LAHUSEN T, VARESIO L, SENDEROWICZ AM: Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. (1999) 59:5433–5437.
   PubMed Web of Science ®Google Scholar
• •A study regarding the anti-angiogenic effect of flavopiridol.
   Google Scholar
• SCHNIER JB, KAUR G, KAISER A et al: Identification ofcytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. (1999) 454:100–104.
   PubMed Web of Science ®Google Scholar
• BIBLE KC, BIBLE RH, JR., KOTTKE TJ et al: Flavopiridolbinds to duplex DNA. Cancer Res. (2000) 60:2419–2428.
   Google Scholar
• JAGER W, ZEMBSCH B, WOLSCHANN P et al: Metabolismof the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. (1998) 62:1861–1873.
   PubMed Web of Science ®Google Scholar
• SENDEROWICZ AM, HEADLEE D, STINSON SF et al.:Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncoi. (1998) 16:2986–2999.
   Web of Science ®Google Scholar
• SCHWARTZ GK, KAUBISCH A, SALTZ L et al.: Phase I trialof sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol. 35th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (1999):614.
   Google Scholar
• BENNETT P, MANI S, O'REILLY S et al.: Phase II trial offlavopiridol in metastatic colorectal cancer: prelimi-nary results. 35th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA (1999):1065.
   Google Scholar
• STADLER WM, VOGELZANG NJ, AMATO R et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol (2000) 18:371–375.
   PubMed Web of Science ®Google Scholar
• HIROSE M, HOSHIYA T, AKAGI K, TAKAHASHI S, HARA Y,ITO N: Effects of green tea catechins in a rat multi-organ carcino genesis model. Carcinogenesis (1993) 14:1549–1553.
   PubMed Web of Science ®Google Scholar
• AZUINE MA, BHIDE SV: Adjuvant chemoprevention ofexperimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. j Ethnophar-macol. (1994) 44:211–217.
   PubMed Web of Science ®Google Scholar
• KOZLUCA 0, OLCAY E, SURUCU S, GURAN Z, KULAKSIZ T, USKENT N: Prevention of doxorubicin induced car diotoxicity by catechin. Cancer Lett. (1996) 99:1–6.
   PubMed Web of Science ®Google Scholar
• MENON LG, KUTTAN R, KUTTAN G: Anti-metastatic activity of curcumin and catechin. Cancer Lett. (1999) 141:159–165.
   PubMed Web of Science ®Google Scholar
• LIAO S, UMEKITA Y, GUO J, KOKONTIS JM, HIIPAKKA RA: Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocate-chin gallate. Cancer Lett. (1995) 96:239–243.
   PubMed Web of Science ®Google Scholar
• GENSLER HL, TIMMERMANN BN, VALCIC S et al.: Preven-tion of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Nutr. Cancer (1996) 26:325–335.
   PubMed Web of Science ®Google Scholar
• YOSHIZAWA S: (-)-Epigallocatechin gallate, the main constituent of Japanese green tea, inhibits tumor promotion of okadaic acid. !Japanese]. Fukuoka Igaku Zasshi - Fukuoka Acta Medica (1996) 87:215–221.
   PubMedGoogle Scholar
• AHMAD N, FEYES DK, NIEMINEN AL, AGARWAL R, MUKHTAR H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl. Cancer Inst. (1997) 89:1881–1886.
   PubMed Web of Science ®Google Scholar
• LIANG YC, LIN-SHIAU SY, CHEN CF, LIN JK: Suppressionof extracellular signals and cell proliferation through EGF receptor bin ding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Biochem. (1997) 67:55–65.
   Web of Science ®Google Scholar
• HIBASAMI H, KOMIYA T, ACHIWA Y et al.: Induction of apoptosis in human stomach cancer cells by green tea catechins. Oncology Rep. (1998) 5:527–529.
   PubMed Web of Science ®Google Scholar
• NAASANI I, SEIMIYA H, TSURUO T: Telomerase telomere shortening and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. (1998) 249:391–396.
   PubMed Web of Science ®Google Scholar
• PASCHKA AG, BUTLER R, YOUNG CY: Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett. (1998) 130:1–7.
   PubMed Web of Science ®Google Scholar
• ISHINO A, MITA S, WATANABE S, SAKAGAMI H: Effect of anticancer drugs, metals and antioxidants on cytotoxic activity of epigallocatechin gallate. AntiCancer Res. (1999) 19:4343–4348.
   PubMed Web of Science ®Google Scholar
• OTSUKA T, OGO T, ETO T, ASANO Y, SUGANUMA M, NIHO Y: Growth inhibition of leukemic cells by (-)-epigallocatechin gallate, the main constituent of green tea. Life Sci. (1998) 63:1397–1403.
   PubMed Web of Science ®Google Scholar
• AUCAMP J, GASPAR A, HARA Y, APOSTOLIDES Z: Inhibi-tion of xanthine oxidase by catechins from tea (Camellia sinensis). AntiCancer Res. (1 9 9 7) 17:4381-4385.
   Google Scholar
• HAYEK T, FUHRMAN B, VAYA J et al.: Reduced progres-sion of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscl Thromb. Vasc. Biol. (1997) 17:2744–2752.
   PubMed Web of Science ®Google Scholar
• PLUMB GW, PASCUAL-TERESA S, SANTOS-BUELGA C, CHEYNIER V, WILLIAMSON G: Antioxidant properties of catechins and proanthocyanidins: effect of polymeri-sation, galloylation and glycosylation. Free Radical Res. (1998) 29:351–358.
   PubMed Web of Science ®Google Scholar
• LOTITO SB, FRAGA CG: (+)-Catechin as antioxidant: mechanisms preventinghuman plasma oxidation and activity in red wines. Biofactors (1999) 10:125–130.
   PubMed Web of Science ®Google Scholar
• SATO K, KANAZAWA A, OTA N, NAKAMURA T, FUJIMOTO K: Dietary supplementation of catechins and alpha-tocopherol accelerates the healing of trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. J Nutr. Sci. Vitaminol. (1998) 44:769–778.
   PubMed Web of Science ®Google Scholar
• SAUCIER CT, WATERHOUSE AL: Synergetic activity of catechin and other antioxidants. J. Agricult. Food Chem. (1999) 47:4491–4494.
   PubMed Web of Science ®Google Scholar
• SAZUKA M, ITOI T, SUZUKI Y, ODANI S, KOIDE T, ISEMURA M: Evidence for the interaction between (-)-epigallocatechin gallate and human plasma proteins fibronectin, fibrinogen and histidine-rich glycoprotein. Biosci. Biotechnol Biochem. (1996) 60:1317–1319.
   PubMed Web of Science ®Google Scholar
• SUGANUMA M, OKABE S, KAI Y, SUEOKA N, SUEOKA E, FUJIKI H: Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. (1999) 59 :44–47.
   PubMed Web of Science ®Google Scholar
• HSU TC, ZHAO Y, WANG RY et al.: Exaggerated precocious centromere separation in cells of a human breast cancer line treated with a green tea extract. Int. J. Oncol. (1998) 12:617–620.
   PubMed Web of Science ®Google Scholar
• NEWMAN RA, HUTTO T, FELIX E, LEE JS, PISTERS KMW, HONG WK: Clinical pharmacology of catechins and caffeine in adult solid tumor patients enrolled in a Phase I trial of green tea extract. 90th Annual Meeting of the American Association of Cancer Research. Philadelphia, PA, USA (1999).
   Google Scholar
• •A Phase I clinical trial of green tea extract.
   Google Scholar
• GOTOH T, YAMADA K, YIN H, ITO A, KATAOKA T, DOHI K: Chemopr even tion of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. Jpn. J. Cancer Res. (1998) 89:137–142.
   PubMedGoogle Scholar
• XU X, DUNCAN AM, MERZ BE, KURZER MS: Effects of soy isoflavones on estrogen and phytoestrogen metabo-lism in premenopausal women. Cancer Epidemiol. Biomarkers Prevent. (1998) 7:1101–1108.
   PubMed Web of Science ®Google Scholar
• THIAGARAJAN DG, BENNINK MR, BOURQUIN LD, KAVAS FA: Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein and calcium. Am. J. Clin. Nutr. (1998) 68:1394S–1399S.
   Google Scholar
• RAUTH S, KICHINA J, GREEN A: Inhibition o f gr owth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemo sensitivity is regulated by cellular p53. Br. J. Cancer (1997) 75:1559–1566.
   PubMed Web of Science ®Google Scholar
• MENON LG, KUTTAN R, NAIR MG, CHANG YC, KUTTANG: Effect of isoflavones genistein and daidzein in the inhibition of lung metastasis in mice induced by B16F-10 melanoma cells. Nutr. Cancer (1998) 30:74–77.
   PubMed Web of Science ®Google Scholar
• CONSTANTINOU Al, KRYGIER AE, MEHTA RR: Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. Am. J. Clin. Nutr. (1998) 68:1426S–1430S.
   Google Scholar
• SU SJ, YEH TM, LEI HY, CHOW NH: The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin. Cancer Res. (2000) 6:230–236.
   PubMed Web of Science ®Google Scholar
• LEE KW, WANG HJ, MURPHY PA, HENDRICH S: Soybeanisoflavone extract suppresses early but not later promotion of hepatocarcinogenesis by phenobarbital in female rat liver. Nutr. Cancer (1995) 24:267–278.
   PubMed Web of Science ®Google Scholar
• WEI H, WEI L, FRENKEL K, BOWEN R, BARNES S: Inhibi-tion of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutt-. Cancer (1993) 20:1–12.
   PubMed Web of Science ®Google Scholar
• WEI H, BOWEN R, CAI Q, BARNES S, WANG Y: Antioxi-dant and antipromotional effects of the soybean isofla-vone genistein. Proc. Soc. Exp. Biol. Med. (1995) 208:124–130.
   PubMed Web of Science ®Google Scholar
• WEI H, CAI Q, RAHN RO: Inhibition of UV light- andFenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein. Carcinogenesis (1996) 17:73–77.
   PubMed Web of Science ®Google Scholar
• FRITZ WA, COWARD L, WANG J, LAMARTINIERE CA: Dietary genistein: perinatal mammary cancer preven-tion, bioavailability and toxicity testing in the rat. Carcinogenesis (1998) 19:2151–2158.
   PubMed Web of Science ®Google Scholar
• ONOZAWA M, KAWAMORI T, BABA M et al: Effects of asoybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn. J. Cancer Res. (1999) 90:393–398.
   PubMedGoogle Scholar
• SHERTZER HG, PUGA A, CHANG C et al: Inhibition ofCYP1A1 enzyme activity in mouse hepatoma cell culture by soybean isoflavones. Chem. Biol. Interact. (1999) 123:31–49.
   PubMed Web of Science ®Google Scholar
• CONSTANTINOU Al, KAMATH N, MURLEY JS: Genisteininactivates bc1-2, delays the G2/M phase of the cell cycle and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur. J Cancer (1998) 34:1927–1934.
   PubMed Web of Science ®Google Scholar
• •A mechanism of action study of genistein.
   Google Scholar
• ZHOU JR, GUGGER ET, TANAKA T, GUO Y, BLACKBURNGL, CLINTON SK: Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. (1999) 129:1628–1635.
   PubMed Web of Science ®Google Scholar
• CAI Q, WET H: Effect of dietary genistein on antioxidantenzyme activities in SENCAR mice. Nutr. Cancer (1996) 25:1–7.
   PubMed Web of Science ®Google Scholar
• KERRY N, ABBEY M: The isoflavone genistein inhibitscopper and peroxyl radical mediated low density lipoprotein oxidation in vitro. Atherosclerosis (1998) 140:341–347.
   PubMed Web of Science ®Google Scholar
• MENG QH, LEWIS P, WAHALA K, ADLERCREUTZ H, TIKKANEN MJ: Incorporation of esterified soybean isoflavones with antioxidant activity into low density lipoprotein. Biochim. Biophys. Acta (1999) 1438:369–376.
   PubMed Web of Science ®Google Scholar
• MENG QH, WAHALA K, ADLERCREUTZ H, TIKKANEN MJ:Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by low density lipoprotein particles into cultured U937 cells. Life Sci. (1999) 65:1695–1705.
   PubMed Web of Science ®Google Scholar
• TRIEU VN, DONG Y, ZHENG Y, UCKUN FM: In vivo antioxidant activity of genistein in a murine model of singlet oxygen-induced cerebral stroke. Radial-. Res. (1999) 152:508–516.
   PubMed Web of Science ®Google Scholar
• SADOWSKA-KROWICKA H, MANNICK EE, OLIVER PD etGenistein and gut inflammation: role of nitric oxide. Proc. Soc. Exp. Biol. Med. (1998) 217:351–357.
   PubMed Web of Science ®Google Scholar
• FANTI P, MONIER-FAUGERE MC, GENG Z et al: The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporosis Int. (1998) 8:274–281.
   PubMed Web of Science ®Google Scholar
• ISHIMI Y, MIYAURA C, OHMURA M eta].: Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Endocrinology (1999) 140:1893–1900.
   Google Scholar
• GAO YH, YAMAGUCHI M: Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem. Pharmacol (1999) 58:767–772.
   PubMed Web of Science ®Google Scholar
• TRIEU VN, UCKUN FM: Genistein is neuroprotective inmurine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. (1999) 258:685–688.
   PubMed Web of Science ®Google Scholar
• EK 0, YANISHEVSKI Y, ZEREN T et al.: In vivo toxicityand pharmacokinetic features of B43(Anti-CD19)-genistein immunoconjugate. Leuk. Lymphoma (1998) 30:389–394.
   Google Scholar
• CHEN CL, LEVINE A, RAO A et al.: Clinical pharmacoki-netics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J. Clin. Pharmacol. (1999) 39:1248–1255.
   PubMed Web of Science ®Google Scholar
• •A Phase I trial of B43-genistein conjugate.
   Google Scholar
• UCKUN FM, NARLA RK, ZEREN T eta].: In vivo toxicity, pharmacokinetics and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin. Cancer Res. (1998) 4:1125–1134.
   Google Scholar
• MYERS DE, SICHENEDER A, CLEMENTSON D et al.: large scale manufacturing of B43 (anti-CD19)-genistein for clinical trials in leukemia and lymphoma. Leuk. Lymphoma (1998) 29:329–338.
   PubMed Web of Science ®Google Scholar
• FORMICA JV, REGELSON W: Review of the biology of Quercetin and related bioflavonoids. Food Chem. Toxicol. (1995) 33:1061–1080.
   PubMed Web of Science ®Google Scholar
• LAROCCA LM, TEOFILI L, MAGGIANO N, PIANTELLI M, RANELLETTI FO, LEONE G: Quercetin and the growth of leukemic progenitors. Leuk Lymphoma (1996) 23:49–53.
   PubMed Web of Science ®Google Scholar
• HERTOG MG, HOLLMAN PC: Potential health effects of the dietary flavonol quercetin. Eur. j Clin. Nutr. (1996) 50:63–71.
   PubMed Web of Science ®Google Scholar
• DAY AJ, WILLIAMSON G: Human metabolism of dietary quercetin glycosides. Basic Life Sci. (1999) 66:415–434.
   PubMedGoogle Scholar
• TERAO J: Dietary flavonoids as antioxidants in vivo: conjugated metabolites of (-)-epicatechin and quercetin participate in antioxidative defense in blood plasma. J Med. Invest (1999) 46:159–168.
   PubMedGoogle Scholar
• GRAEFE EU, DERENDORF H, VEIT M: Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther. (1999) 37:219–233.
   PubMed Web of Science ®Google Scholar
• FERRY DR, SMITH A, MALKHANDI J et al.: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. (1996) 4:659–668.
   Google Scholar
• WANG HK, MORRIS-NATSCHKE S, LEE KH: Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Med. Res. Rev. (1997) 17:367–425.
   PubMed Web of Science ®Google Scholar